Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2024.Jan.31

Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial

2024.Jan.03

OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial

2023.Dec.29

Announcement on behalf of Amaran that its institutional director changes its representative

2023.Dec.29

The Company’s Board of Directors nominated Dr. Kung-Yee Liang to serve as the Chairperson of the Board

2023.Dec.29

Announcement on behalf of OBIGEN that its institutional director changes its representative

2023.Dec.21

Announcement that the institutional director of OBI, Sheng Cheng Investment Co., Ltd., changes its representative

2023.Dec.20

Announcement of the resignation of natural-person director

2023.Dec.20

Announcement on behalf of OBIGEN of the resignation of its institutional director

2023.Dec.20

OBI announces termination of BCVax, OBI-866, and OBI-999

2023.Dec.20

Announcement of resignation of the Chairperson

News

Latest News

Events

Latest events